@ UNIVERSITY OF NANTES
the bitterness of glucose
Dr Prieur is an associate professor at the University of Nantes and is studying the mechanism involved in adipocyte dysfunction and the associated cardiometabolic complications with a focus on diabetic cardiomyopathy
@ IHU-ICAN, AP-HP, INSERM, SORBONNE UNIVERSITY
Novel therapies with SGLT2
Richard Isnard is Professor of Cardiology at University Paris-Sorbonne and at Hopital Pitié-Salpêtrière in Paris, where he coordinates heart failure programs. His main research interest is related to echocardiography, heart failure and cardiomyopathies. He has participated in many heart failure trials as investigator and was the principal investigator of the Eurogene Heart Failure study which focused on the genetics of cardiomyopathies. He has been involved in several French and European survey in heart failure (OFICA, FRESH, EORP). Recently, he chaired the Echo Core Lab of the Edify Study. He has been the Chairman of the French Working Group on Heart Failure and Cardiomyopathies and is a Fellow of the European Societey of Cardiology and a member of the Heart Failure Association. He has authored or co-authored more than 160 peer-reviewed publication. He is also deeply involved in cardiology training as chairman of the French National College of Teaching Cardiologists
@ IHU-ICAN, AP-HP, INSERM, SORBONNE UNIVERSITY
Lipodystrophy as a
Corinne Vigouroux (MD, PhD) is Professor of Cellular Biology at Sorbonne University, and Hospital Practionner in Molecular Genetics and Endocrinology at Assistance-Publique Hôpitaux de Paris, where she coordinates the National Reference network for Rare Diseases of Insulin Sensitivity and Insulin Secretion. Her research group at Saint-Antoine Research Center (Bruno Feve’s team, Inserm U938, Paris, France) conducts translational studies focusing on molecular and cellular pathophysiology in the field of severe insulin resistance and/or lipodystrophy syndromes.
@ PASTEUR INSTITUTE, LILLE
Circadian control of metabolism & inflammation:
implications for cardiometabolic disease development
Research in Dr Helene Duez' team (Lille University) is oriented to the role of nuclear receptors in circadian biology. We study the impact of a dysregulated biological clock in the development of metabolic and cardiovascular diseases.
Blocking granzyme B producing cytotoxic CD8+ T cells protects against post-ischemic cardiac remodeling
Professor Ait-Oufella is a Professor of Cardiology and Intensive Care Medicine at Pierre-et-Marie Curie University, and head of Team 5 “Immuno-metabolic mechanisms of cardiovascular disease” at Inserm U970, Paris, France. He has extensive expertise in the immune mechanisms of cardiovascular diseases, especially the role of T and B cells. He is also interested in studying the crosstalks between innate and adaptive immune responses.
@ OXFORD UNIVERSITY
in cardiometabolic disease
Dr Kerstin Timm is a British Heart Foundation Immediate Postdoctoral Basic Science Research Fellow at the Department of Physiology Anatomy and Genetics, a Stipendiary Lecturer in Medicine at Somerville College and a Lecturer in Metabolism at Corpus Christi College, University of Oxford. Her research focuses on the toxic side-effects of the chemotherapeutic agent doxorubicin on the heart. Specifically, she is using hyperpolarized MRI to study metabolic fluxes in a model of doxorubicin-induced heart failure.
@ GRONINGEN UNIVERSITY
for coronary artery disease
Rozemarijn Vliegenthart (MD, PhD, EBCR, Prof) obtained her MD degree (cum laude) in 2005. She holds an MSc degree in Clinical Epidemiology from the Netherlands Institute for Health Sciences, and finished her PhD degree in 2003. Vliegenthart is (co-)author of over 200 papers (H index 39) and has acquired a number of grants in cardiothoracic imaging as applicant or co-investigator. She is the current secretary of the European Society of Cardiovascular Radiology. Prof Vliegenthart was appointed Tenure track professor in cardiothoracic imaging at the Rijksuniversiteit Groningen in 2015.
CELIA MP RODRIGUES
@ LISBON UNIVERSITY
Metabolic liver disease
Full Professor at the University of Lisbon and Director of the Research Institute for Medicines (iMed.ULisboa). Her central research focus is to discover biomarkers of disease and mechanism-based molecular targets for therapeutic intervention, by focusing on signalling pathways, genetics and epigentics involved in cell death, differentiation and proliferation. She uses patient samples as well as experimental models of disease to test therapeutic strategies at preclinical level. She is past governing board member of the European Association for the Study of the Liver (EASL).
@ COCHIN INSTITUTE
Insuling signaling & glucotoxicity
Catherine Postic, PhD, is a research group leader in the Department of Endocrinology Metabolism and Diabetes at the Cochin Institute, INSERM U1016, CNRS UMR 8104 Université René Descartes in Paris. Dr. Catherine Postic has earned her doctorate at the University Paris 7 in Paris. She completed post-doctoral work at Vanderbilt University in Nashville, TN USA. Her long time interest in the control of hepatic metabolism prompted her to study the function and the regulation of the transcription factor ChREBP. Using both physiological and metabolic approaches her group made significant progress in understanding the regulation of ChREBP by glucose and assessing its function in the physiopathology of Non Alcoholic Fatty Liver Diseases (NAFLD).
@ MARSEILLE MEDICAL GENETICS,
AIX-MARSEILLE UNIVERSITY, TIMONE HOSPITAL
The role of vitamin D in cardiogenesis
2003-present INSERM (French National Institute of Health and Medical Research) Tenured Career Scientist Directeur de Recherche
1995- 2000 Visiting Scientist, Mayo Clinic,
Division Cardiovascular Diseases, Rochester, MN, USA,
May 1992-April 1993; July-October 1994 Visiting Scholar, Dept of Pharmacology, University of California at San Diego, La Jolla CA
March 2010-March 2011 Sabbatical UCSD dept Medecine- La Jolla, CA
Themes of research from Excitation-Contraction coupling, signal ttransduction in the heart to developmental biology of the heart.
Eric Villard is a geneticist and molecular biologist interested in cardiomyopathy genomics approaches to further understand the pathophysiological mechanisms of these devastating diseases. Eric Villard’s group has identified many genes responsible for dilated cardiomyopathies in familial and sporadic forms through pioneer GWAS study in the field, revealing proteostasis as a strong candidate pathway regulating heart failure in humans. His current interests are focused on the validation of this exciting hypothesis using innovative approaches such as Crispr-Cas9 genome editing, iPS-derived cardiomyocytes from patients, and derived 3D-Engineered Heart Tissue (EHT), genetically-modified mice models and AAV-based therapeutic approaches.
@ UNIVERSITY OF EDINBURGH
Stem cell-based modelling of human
disorders of growth & insulin action
Prof Semple is based at the University of Edinburgh. His clinical and research interests centre on monogenic human disorders of growth and insulin action, encompassing insulin/PI3K/AKT signalling and primary disorders of adipose tissue function. Such rare disorders are studied in humans, cells and animals to improve understanding of pandemic “insulin resistance”, and of the mechanisms linking it to major disease, and on translating findings from the research laboratory into clinical benefits for patients.